Furthermore, numerous clinical trials with patients suffering from diabetes or heart failure have shown that the use of selective SGLT-2 inhibitors is well tolerated and safe [13,14,15,16,17,18,19] and these drugs can also be used in patients without diabetes [53,54]. Here, SLC5A2 is linked to heart failure.